All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Race Is Predictive of Survival Outcomes With Intensive Chemotherapy Independent of Cytogenetics in AML

December 6th 2025

Findings from a retrospective analysis identified Black race as an independent predictor of inferior survival outcomes with intensive chemotherapy in AML.

Lisaftoclax Displays Activity in R/R CLL/SLL

December 6th 2025

Lisaftoclax demonstrated efficacy and safety for the treatment of patients with relapsed/refractory CLL/SLL.

BGB-16673 Is Safe, Highly Active Regardless of Baseline Mutations or High-Risk Features in R/R CLL/SLL

December 6th 2025

In the CaDAnCe-101 study, BGB-16673 was tolerable, effective, and showed sustained disease control in high-risk, heavily pretreated, relapsed/refractory CLL/SLL.

Zanubrutinib Plus R-CHOP Is Active in Untreated DLBCL With Specific Gene Expression

December 6th 2025

Zanubrutinib plus R-CHOP produced a high ORR and CR rate in untreated DLBCL with certain gene expression.

Families Face Financial Hardships in Pediatric ALL

December 6th 2025

Thirty percent of families of pediatric patients with ALL receiving chemotherapy experienced catastrophic financial toxicities.

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

December 6th 2025

Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.

Venetoclax-Based, Fixed-Duration Regimens Match Continuous Ibrutinib in Frontline CLL

December 6th 2025

Fixed-duration venetoclax combinations delivered PFS comparable with continuous ibrutinib in the phase 3 CLL17 trial.

TBI-Free Conditioning Maintains Strong Outcomes in Pediatric and Young Adult B-Cell ALL

December 6th 2025

The phase 2 EndRAD study found that removing TBI from conditioning did not compromise efficacy in pediatric or young adult patients with B-cell ALL.

Adjuvant Atezolizumab Generates DFS, OS Benefit Regardless of Tumor Size, Nodal Status, and Prior NAC in ctDNA+ MIBC

December 6th 2025

Findings from an exploratory analysis of IMvigor011 support the use of serial ctDNA testing to guide atezolizumab use in MIBC.

Intravesical Cretostimogene Grenadenorepvec Is Active in BCG-Naive High-Risk NMIBC

December 6th 2025

Intravesical cretostimogene grenadenorepvec was efficacious and safe in high-risk BCG-naive non–muscle-invasive bladder cancer.

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC

December 6th 2025

Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC

December 6th 2025

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age

December 6th 2025

Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Experts Prepare for Several Key MCL Presentations at ASH 2025

December 5th 2025

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

Management of Peripheral Neuropathy Does Not Compromise Survival Benefit With Frontline Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

December 5th 2025

Peripheral neuropathy was linked with improved efficacy outcomes after treatment with first-line enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years

December 5th 2025

At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Meta Analyses Show Suboptimal Efficacy With BCG in Metachronous NMIBC

December 5th 2025

Those with metachronous NMIBC experienced poorer outcomes with BCG vs those with primary NMIBC.

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

December 5th 2025

A look at the top multiple myeloma abstracts set to be presented at the 2025 ASH Annual Meeting.

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, experts in myeloproliferative neoplasms share the most anticipated research being presented during the meeting.

Sylvester’s Researchers Lead Major Treatment Overhauls For Acute Myeloid Leukemia

December 5th 2025

Researchers at Sylvester Comprehensive Cancer Center lead the way in innovative AML treatments.